Leukemia initiating cells (LICs) are defined by their ability to generate leukemias in animal models and to self-renew by repopulating serial recipients. Recent findings suggest that multiple sub-populations of acute leukemia cells are capable of engrafting immune deficient mice raise important questions about the biology of these diseases. [1] [2] [3] If several cell populations have LIC properties, what are the relationships of these stem cell populations to each other and which populations are most important to target with therapy? To address these questions, it is crucial to utilize assays that are capable of identifying any leukemia cells that possess stem cell properties. The recently developed NOD/LtSz-scid IL-2Rg c null (NSG) mouse is now considered a more permissive host for the growth and development of normal and acute myeloid leukemia cells than the nonobese diabetic severe combined immune deficient (NOD/SCID) strain. 4, 5 In acute lymphoblastic leukemia (ALL) engraftment of high-risk cases has been reported to be slower in NOD/SCID than NSG but otherwise leukemias developed in both strains. 6 However, another study reported that engraftment of T-ALL cells was improved using NSG mice. 7 Observations that different populations of cells can engraft different mouse strains raise questions as to how the reports that used only NOD/ SCID mice should be interpreted. NSG and NOD/SCID strains have not previously been directly and quantitatively compared for engraftment potential of pediatric LIC sub-populations using the same source of cells. Such studies should provide clear information as to the permissiveness of each strain and which sub-populations have LIC potential.
In this investigation we have compared the engraftment of childhood T-ALL and BCP-ALL cases (detailed in Supplementary (Figure 1 ). Engraftment levels in NSG mice were significantly higher than the levels attained using NOD/SCID mice (Pp0.05), with the exception of only 2 cases, 1 T-ALL and 1 c-ALL, where there were no significant differences between the strains. The length of time to engraftment was shorter with NSG recipients than with NOD/SCIDs (P ¼ 0.02, Table 1 ). The presence of leukemia cells in NSG mice could usually be confirmed within 7 weeks while it could take up to 9 weeks to detect leukemia cells in NOD/SCID mice. Examples of detailed analyses of the length of time to engraftment of high, intermediate and low engrafting samples are shown in Supplementary Figure 1A . Leukemia cells could usually be detected 2 weeks earlier in the peripheral blood or bone marrow of NSG mice than with NOD/SCID recipients. Even in cases where engraftment levels were relatively low, leukemia cells could be detected 2-3 weeks earlier in the NSG recipients. In addition, 2 to 100-fold fewer cells were required to engraft NSG mice compared with NOD/ SCID mice in both ALL subtypes (Supplementary Figure 1B) . Cells from 1 T-ALL case could not engraft NOD/SCID mice but could engraft the NSG strain. Transplantation of one pediatric and four adult T-ALL samples was reported to be more successful in NSG mice than NOD/SCID mice. 7 Our findings agree with this report and suggest that the NSG strain is a more permissive host for engraftment of pediatric leukemias. However, Morisot et al. 6 reported comparable engraftment of four high-risk and one standard risk B-ALL cases in these strains. In our study similar levels of engraftment were achieved in these strains with two high-risk patients but in the remaining cases engraftment was higher in NSG mice, regardless of risk category or whether diagnostic or relapse samples were used. Our findings suggest that the rate of engraftment was faster in NSG mice in accordance with those of Morisot et al. 6 To address the question of whether multiple sub-populations of ALL cells have LIC content we compared sorted T-and B-ALL populations for their potential to engraft both strains (see Supplementary material for details). In the T-ALL cases, multiple populations were capable of engrafting NSG mice (Table 1 ). In 2 of 4 cases, reasonable levels of engraftment were observed with the CD34 þ /CD7 þ (32-98%) and CD34 À (90-98%) subpopulations. In contrast, only very low levels of engraftment were observed when these sub-populations were inoculated into NOD/SCIDs. The CD34 þ /CD7 À subfraction represented only 0.81 ± 0.5% of the total blast population in these cases at sorting. However, engraftment with this subfraction was observed in both NSG and NOD/SCID mice in every case, although higher levels were detected in NSG mice (21-99%) than in NOD/SCID (4-86%). Engraftment of CD34 þ /CD7 À cells was more rapid than that of unsorted cells or any other population regardless of the mouse strain. Moreover, 30 to 100-fold fewer CD34
þ /CD7 À cells were required to achieve engraftment levels equivalent to that observed with CD34 À cells in NSG. Fluorescence in situ hybridization analyses confirmed engraftment of leukemia cells in the animals. The inoculated CD34 þ /CD7 À cells underwent differentiation in vivo to produce leukemias with similar immunophenotypes to the patient samples at biopsy (Table 2) . A minor fraction of these grafts were CD34 þ /CD7 À (0.8 ± 0.3%) consistent with self-renewal of this subfraction. When we investigated the self-renewal ability of these T-ALL sub-populations in both strains, engraftment of cells from recipients of CD34 þ /CD7 þ and CD34 À sub-populations was limited to 2-3 rounds (Table 2 , Supplementary Figure 2 ). In contrast, engraftment levels remained relatively stable after 3-5 rounds of transplantation of cells from recipients of CD34 þ /CD7 À cells. Engraftment was more rapid in these serial xenografts and consequently animals had to be killed at earlier time points than the primary recipients. Our finding suggests that multiple T-ALL populations can engraft NSG mice concurs with a report of engraftment of CD7 þ /CD1a À and CD7 þ /CD1a þ adult T-ALL cells in NSG mice, whereas engraftment was achieved in NOD/SCID mice with the CD7 þ /CD1a À sub-population only. 7 Interestingly, when leukemia cells from primary NOD/SCID mice, that had been engrafted with CD7
þ /CD1a À cells were re-sorted both CD7
þ /CD1a À and CD7 þ /CD1a þ cells could engraft NSG mice. 7 This observation suggests that the NOD/SCID environment may have had a role in the selection and adaptation of LICs, resulting in two populations with engrafting potential in NSG. This finding provides evidence for the concept of primary xenograft selection of cells with engrafting capacity. CD34 þ /CD19 À and CD34 À B-ALL sub-populations were also found to be capable of engrafting NSG mice (Table 1) . Engraftment was higher in recipients of CD34 þ /CD19 À cells (12-97%), where 4 to 200-fold fewer cells were required compared with the levels obtained using CD34
À cells (0.7-31%). The CD34 þ /CD19 À sub-population was also capable of engrafting NOD/SCID mice in all cases but engraftment levels were reduced (0.7-70%), sometimes significantly, compared with levels observed in NSG mice. Engraftment of NOD/SCID mice with CD34 À B-ALL cells was observed in one sample only and the levels of engraftment were sevenfold lower than attained in NSG mice. As we have observed previously, 8 the inoculated CD34 þ /CD19 À cells differentiated in vivo to give rise to leukemias that were typical of the patient samples (Table 2) . However, a proportion of the grafts remained CD34 þ /CD19 À (1.1 ± 0.5%), indicating selfrenewal of these cells. The finding suggests that multiple pediatric B-ALL sub-populations can engraft NSG mice has been reported previously.
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þ from mainly highrisk pediatric ALL cases were capable of engrafting. Similar to our study, the doses of CD34 þ /CD19 À cells were lower, because of the rarity of this population, but had engrafting capacity that was comparable with the other sub-populations. In another study,
þ cells from ETV6-RUNX1 cases were reported to engraft NSG mice. 3 However, we did not observe engraftment with CD34 þ /CD19 þ subfractions. Heterogeneity amongst patient samples may be a reason for the observed differences in LIC populations. The use of intrafemoral inoculation and sampling vs intravenous techniques and different sorting strategies may also be contributing factors. It is also possible that the binding of CD19 to ALL cells may have primed these cells for destruction. However, in experiments using unsorted cells we confirmed that there was no reduction of engraftment using Letters to the Editor cells that had been stained with anti-CD19 antibody compared with cells stained with isotype controls. Therefore, we do not believe the lack of engraftment with CD19 þ cells in our cohort of patients can be attributed to antibody-mediated clearance of repopulating cells. In this study, the CD34 þ /CD19 À and CD34 À populations were also capable of self-renewal in NSG mice. Engraftment attained with CD34 þ /CD19 À cells remained relatively high and stable throughout secondary and tertiary transplants. Engraftment of cells from animals inoculated with CD34
À B-ALL cells was reduced in secondary recipients and no engraftment was observed in tertiary recipients. Reduced levels of engraftment with some leukemia sub-populations have been reported by other groups and suggest that some LIC sub-populations have greater self-renewal ability than others. 2, 5 These findings, in both T-and B-ALL samples, suggest that a number of intrinsically distinct sub-populations of LICs exist in pediatric ALL cases. Such findings add to the evidence that leukemia evolution may occur in a branching manner rather than a hierarchical one. 3 However, the phenotypically immature LICs we have identified had the potential to differentiate in vivo and may give rise to LICs with more restricted regenerative capacity. This would suggest they were organized in hierarchical manner. A similar phenomenon has been reported in acute myeloid leukemia by Goardon et could give rise to the more mature population in vivo. However, the CD34 þ /CD38 þ /CD45RA þ cells could not generate the immature population. It is possible that as leukemias evolve the frequency of LICs increases together with their genetic variation and they eventually progress to a state where LICs have a branching evolution rather than a hierarchical one. Further studies are warranted using more sophisticated assays that incorporate cell tracking techniques to discriminate between LICs with extensive self-renewal ability and those that can proliferate but have limited self-renewal capacity. These studies should be combined with genetic analyses of the LIC populations. This would enable us to gain a better understanding of the molecular characteristics of each individual LIC subclone and their potential role in disease progression.
Our data demonstrate that the NSG strain is a more permissive host for engraftment of pediatric leukemias irrespective of prognostic indicators or disease status. NSG mice permitted engraftment of sub-populations that were not observed using the NOD/SCID strain. The use of NSG mice in several human cancer studies has revealed that tumorigenic cells are more common and may be more diverse than data from NOD/SCID mice suggested. [5] [6] [7] The discoveries that a few populations can initiate leukemia in mouse models and that new populations of LICs can be detected following an initial round of transplantation in these models raise questions as to how relevant these LICs are in the patient setting. The environment within a mouse model is likely to differ from that in human leukemias, therefore, populations that form leukemias Abbreviations: ALL, acute lymphoblastic leukemia; NOD/SCID, nonobese diabetic severe combined immune deficient.
Letters to the Editor in mice may differ from those that contribute to disease progression in the patients. Consequently, while it is important for future studies to identify and characterize cells that possess the capacity to regenerate all aspects of the leukemia, it will be essential to determine whether there is any correlation in biological properties of LICs identified in these model systems with the response of the patients to therapy. 
